Insulet (NASDAQ:PODD) Rating Lowered to "Hold" at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn downgraded Insulet from a "strong‑buy" to a "hold" in a report issued Friday.
• Multiple firms have cut target prices (JPMorgan $415→$340, Goldman $326→$277, Truist $360→$315, Stifel $370→$350), yet the analyst consensus remains a Moderate Buy with a $327.24 average target.
• Insulet posted a Q1 beat (EPS $1.55 vs. $1.48; revenue $783.8M vs. $768.3M), but the stock is trading near its 12‑month low (opened $189.56, 12‑month low $186.25) with a market cap of about $13.1B and a P/E of ~54x.

Insulet (NASDAQ:PODD - Get Free Report) was downgraded by research analysts at Rothschild & Co Redburn from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered their target price on Insulet from $415.00 to $340.00 and set an "overweight" rating for the company in a research note on Thursday, February 19th. The Goldman Sachs Group lowered their target price on Insulet from $326.00 to $277.00 and set a "buy" rating for the company in a research note on Wednesday, April 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Insulet in a research note on Thursday, January 22nd. Truist Financial lowered their target price on Insulet from $360.00 to $315.00 and set a "buy" rating for the company in a research note on Wednesday, April 15th. Finally, Stifel Nicolaus lowered their target price on Insulet from $370.00 to $350.00 and set a "buy" rating for the company in a research note on Wednesday, February 4th. Eighteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $327.24.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $189.56 on Friday. The firm has a market capitalization of $13.13 billion, a PE ratio of 54.16, a P/E/G ratio of 1.15 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The business has a 50-day moving average of $222.23 and a two-hundred day moving average of $271.72. Insulet has a 12 month low of $186.25 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm's revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 earnings per share. As a group, research analysts forecast that Insulet will post 6.16 earnings per share for the current year.

Insider Activity

In related news, Director Michael R. Minogue bought 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.39% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Winnow Wealth LLC bought a new stake in shares of Insulet in the 3rd quarter worth approximately $862,000. Nordea Investment Management AB lifted its holdings in shares of Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier's stock worth $157,128,000 after purchasing an additional 142,922 shares during the last quarter. Machina Capital S.A.S. acquired a new stake in Insulet in the 3rd quarter valued at approximately $2,778,000. Jain Global LLC increased its position in Insulet by 148.2% in the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier's stock valued at $32,945,000 after acquiring an additional 63,719 shares during the period. Finally, ING Groep NV increased its position in Insulet by 88.5% in the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier's stock valued at $5,341,000 after acquiring an additional 8,123 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.